The Current and Future Roles of Precision Oncology in Advanced Breast Cancer

J Nucl Med. 2024 Mar 1;65(3):349-356. doi: 10.2967/jnumed.122.264882.

Abstract

Breast cancer is a common but heterogeneous disease characterized by several biologic features, including tumor grade, hormone receptor status, human epidermal growth factor receptor 2 status, and gene expression assays. These biologic and genomic features drive treatment decisions. In the advanced disease setting, inter- and intrapatient tumor heterogeneity is increasingly recognized as a challenge for optimizing treatment. Recent evidence and the recent approval of novel radiopharmaceuticals have increased recognition and acceptance of the potential of molecular imaging as a biomarker to impact and guide management decisions for advanced breast cancer.

Keywords: FDG; FES; PET; breast cancer; molecular imaging; precision.

MeSH terms

  • Biological Products*
  • Humans
  • Medical Oncology
  • Neoplasms*
  • Precision Medicine
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Biological Products